Orphan drugs and the NHS: should we value rarity?

@article{McCabe2005OrphanDA,
  title={Orphan drugs and the NHS: should we value rarity?},
  author={Christopher McCabe and Karl Claxton and Aki Tsuchiya},
  journal={BMJ},
  year={2005},
  volume={331 7523},
  pages={1016-9}
}
Related Discussions
This paper has been referenced on Twitter 28 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2018

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2018

Prioritizing Rare Diseases: Psychological Effects Influencing Medical Decision Making.

Medical decision making : an international journal of the Society for Medical Decision Making • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…